secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001193125-25-179466
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Kalaris Therapeutics stockholders elect two Class II directors, ratify Deloitte as auditor
--------------------------------------------------------------------------------

- Srinivas Akkaraju and Andrew Oxtoby elected as Class II directors for three-year terms expiring 2028.
- Akkaraju: 14,626,646 for, 144,695 withheld; Oxtoby: 14,668,424 for, 102,917 withheld.
- Ratification of Deloitte & Touche as independent auditor for FY2025 approved with 16,090,928 for, 6,975 against, 1,786 abstain.
- Broker non-votes of 1,328,348 on director elections due to routine matters.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312525179466/0001193125-25-179466-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312525179466/d885835d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-179466

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer